1. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
- Author
-
H Inzunza, S. Averbuch, Christopher T. Harbison, Jr Jf Novotny, John Cogswell, and Christine Horak
- Subjects
Oncology ,medicine.medical_specialty ,Immune checkpoint inhibitors ,Programmed Cell Death 1 Receptor ,Antineoplastic Agents ,Bioinformatics ,B7-H1 Antigen ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Neoplasms ,Medicine ,Humans ,030212 general & internal medicine ,Clinical Trials as Topic ,business.industry ,Anti pd 1 ,Antibodies, Monoclonal ,Hematology ,Industry Corner: Perspectives and Controversies ,Nivolumab ,030220 oncology & carcinogenesis ,Immunohistochemistry ,business - Abstract
The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx assay may be used to determine tumor PD-L1 expression as a complementary and informative test.
- Published
- 2016